Dr. Hong Liu Joins as the VP of Clinical Development at Anticancer...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Dr. Hong Liu Joins as the VP of Clinical Development at Anticancer Bioscience

Pharma Tech Outlook | Wednesday, July 21, 2021

Dr. Hong Liu is the new VP of Clinical Development at Anticancer Bioscience (ACB), a leader in synthetic lethal methods to precision oncology.

FREMONT, CA: Dr. Hong Liu has been appointed as the VP of Clinical Development at Anticancer Bioscience (ACB), a leader in synthetic lethal methods to precision oncology. He will be located in Chengdu and San Francisco as a physician-scientist.

The J. Michael Bishop Institute of Cancer Research's inventions are being commercialized by ACB. Dr. Liu earlier worked at the University of California, San Francisco with Nobel laureate Dr. J. Michael Bishop and ACB's Founder, President, and CEO, Dun Yang. Dr. Liu will oversee the development of ACB's clinical strategy and the production of data packages and IND filings with the US Food and Drug Administration.

ACB presently employs about 50 people across its locations in China, India, the United Kingdom, and the United States and is growing as it advances its discovery programs closer to clinical development. In 2022, the company hopes to advance at least one of its five programs into clinical studies in the United States.

Welcoming Dr. Hong Liu to the team, ACB's Founder, President, and CEO, Dun Yang, PhD, said: "I am delighted that Dr. Liu is joining our team as we continue our development towards being a clinical stage company. As a highly experienced R&D leader in the field of oncology drug development, Dr. Liu will be a great addition to our world-class team as we progress our pipeline of assets, focused on synthetic lethality approaches. His appointment supports our ongoing mission to grow ACB into a leading international precision oncology company."

Dr. Liu commented on his appointment: "I welcome the opportunity of taking cancer drug candidates from IND-filing, and into the clinic. I am excited to be joining the ambitious team at ACB that is pioneering synthetic lethal approaches to cancer treatment and look forward to using my experience in oncology drug development to advance ACB's unique pipeline of MYC-synthetic lethal drugs."

ACB is pursuing Series A financing to advance at least one of its MYC-SL medicines into clinical trials after raising CNY131 million (about USD21 million) in seed funding to fuel its discovery research.

Weekly Brief

Read Also